GGrantIndex
← Leaderboards

Massachusetts Eye And Ear Infirmary

Boston, MA

Compare ↔
$589,273,606
Total funding
389
Grants

Funding over time

peak $49.1M · FY2005–25
$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$554,015,155 · 357
DOD$32,988,286 · 28
CDC$1,500,000 · 1
NSF$770,165 · 3

By mechanism

R01$363,107,050 · 143
—$33,758,451 · 31
P50$32,979,085 · 16
P01$31,181,391 · 30
U01$24,307,452 · 7
U24$15,174,500 · 4

Investigators at Massachusetts Eye And Ear Infirmary

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

1Qin Liu$2,373,4721 gr2Yanli Wang$637,5001 gr3Hamid Motallebzadeh$549,3921 gr

Emerging Leaders

6–10 yrs in

1Artur Indzhykulian$5,191,6814 gr2Ayellet Vered Segre$3,794,2431 gr3Gopalan Gnanaguru$3,406,4863 gr4Kinga Bujakowska$2,846,2902 gr5Deeba Husain$2,799,4401 gr6Benjamin Bleier$2,546,3161 gr7Corinna M Bauer$2,108,7001 gr8Jason Comander$2,099,5001 gr

All-Time

Most funded here, all years

1Janey L Wiggs$34,898,49313 gr2Vadim Y Arshavsky$23,354,3639 gr3Kristina Simonyan$20,548,7036 gr4Michael S. Gilmore$20,031,06717 gr5Bertrand Delgutte$14,896,8572 gr6Daniel M Merfeld$14,136,1929 gr7Richard F Lewis$13,971,83910 gr8M. Charles Liberman$13,861,7122 gr

Largest grants

AAV-mediated editing to treat human autosomal dominant hearing loss DFNA41 and DFNA2$3,314,560
U01 · FY2024 · TR
AAV-mediated editing to treat human autosomal dominant hearing loss DFNA41 and DFNA2$3,227,062
U01 · FY2025 · TR
R&D-OTHER SVC & DEVELOP-B RES$2,915,180
N01 · FY2009 · DC
VISION RESTORATION WITH A COLLAGEN CROSSLINKED BOSTON KERATOPROSTHESIS UNIT$2,773,704
· FY2015 · Department of the Army
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,701,343
P50 · FY2022 · DC
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,684,344
P50 · FY2023 · DC
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,684,343
P50 · FY2024 · DC
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,684,343
P50 · FY2025 · DC
EX VIVO CORNEAL CROSS-LINKING FOR VASCULARIZED HIGH-RISK KERATOPLASTY (EXCROSSV)$2,553,092
· FY2024 · Defense Health Agency
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,509,086
P50 · FY2017 · DC
Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor$2,478,460
P50 · FY2021 · DC
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,371,694
P50 · FY2019 · DC
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,371,694
P50 · FY2020 · DC
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,371,694
P50 · FY2018 · DC
Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor$2,365,586
P50 · FY2022 · DC
Harvard-wide Program on Antibiotic Resistance$2,362,774
P01 · FY2022 · AI
Cochlear Synaptopathy: Prevalence, Diagnosis and Functional Consequences$2,361,915
P50 · FY2021 · DC
Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor$2,358,689
P50 · FY2024 · DC
Next-generation clinical phenotyping and pathophysiology of laryngeal dystonia and voice tremor$2,353,405
P50 · FY2023 · DC
SAFETY AND EFFICACY OF BEVACIZUMAB IN HIGH-RISK CORNEAL TRANSPLANT SURVIVAL$2,345,534
· FY2012 · Department of the Army